Colombian-Canadian hashish agency Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), has introduced the supply of its first EU-GMP medical hashish product to Germany. Working with German firm Nimbus Health, Khiron merchandise have been stocked within the Nimbus warehouse and are able to be prescribed to sufferers by way of a community of 300 German pharmacies.
This represents a brand new income stream for Khiron and positions its European group to execute on its German medical technique. Leveraging Nimbus Health’s massive distribution community and Khiron’s ongoing investments in doctor schooling, the Canadian listed agency with Colombian operations will deal with indications similar to nervousness, substance use dysfunction, and migraines, addressing affected person wants and bettering entry to medical hashish.
The launch product is Khiron’s 1/14 high-CBD flower, which can deal with indications similar to nervousness, substance use dysfunction, and migraines, addressing affected person wants and bettering entry to medical hashish.
“Since signing our distribution agreement with Nimbus Health in 2020, the company’s European Sales and Marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the UK and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products,” mentioned Tejinder Virk, President of Khiron Europe.
Franziska Katterbach, Managing Director & Chief Legal Officer for Khiron Europe based mostly in Frankfurt, commented, “I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany’s strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients.”